Discovery of the GSH responsive “Y-PROTACs” targeting ALK and CDK4/6 as a potential treatment for cancer
Shirui Wang, Dan Luo, Chunlan Pu, Xinyu Ma, Hongjia Zhang, Zhanzhan Feng, Rui Deng, Su Yu, Yuanyuan Liu, Qing Huang, Rui Li
Journal:EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
IF:6.7
DOI:10.1016/j.ejmech.2022.115082
PMID:36628851
Published:2023-01-01
research field:
Abstract
Combination of different molecular target inhibitors is an available method to improve the therapeutic effect on tumors. Herein, to achieve both tumor cell targeting and ALK degradation & CDK4/6 inhibition in one molecule, we designed and synthesized a novel GSH responsive “Y-PROTACs”, Y5-3, a highly potent molecule with an IC 50 value of 90 nM against H3122 cells, which can be cleaved into ALK PROTAC and CDK4/6 inhibitor moieties in tumor cells. Mechanism studies revealed that Y5-3 exert anti-tumor proliferation activity in vitro not only by ALK degradation and CDK4/6 inhibition, but also by ALK/CDK4 dual degradation. These properties make Y5-3 a GSH responsive multifunctional antitumor agent , and our work provide a new strategy for the development of multifunctional PROTACs.
本文使用的Yeasen产品


